GGrantIndex
Sort

40,608 grants matching prostate cancer

Analysis of Blood Borne Markers in Hormone Sensitive Metastatic Prostate Cancer

$481,793
Christopher J Sweeney · Dana-Farber Cancer Inst · R01 · FY2017 · CA

Cooperativity of TMPRSS2-ERG fusion with p53 inactivation in prostate cancer pathogenesis

$481,745
Liewei Wang · Mayo Clinic Rochester · R01 · FY2023 · CA

Non-coding RNAs for Epigenetic Transcriptional Silencing in Prostate Cancer

$481,734
Martin John Walsh · Icahn School Of Medicine At Mount Sinai · R01 · FY2012 · CA

Understanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistance

$481,696
Yu Chen · Sloan-Kettering Inst Can Research · R01 · FY2019 · CA

Breaking down tumor immune privilege through targeted hypoxia reduction

$481,691
Michael A. Curran · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA

Breaking down tumor immune privilege through targeted hypoxia reduction

$481,691
Michael A. Curran · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA

TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE

$481,629
Harvard University (Medical School) · R01 · FY2001 · CA

The Molecular Profile of Prostate Tumors in African-American Men

$481,515
Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Deciphering the molecular mechanisms of histone code recognition by ATAD2/B

$481,491
Karen Champagne Glass · Albany College Of Pharmacy · R01 · FY2020 · GM

Hybrid Plasma Markers that Complement CT Imaging for Early Lung Cancer Detection

$481,475
Paul D Lampe · Fred Hutchinson Cancer Research Center · U01 · FY2018 · CA

Genotypic and Phenotypic Studies of Inflammation in PCPT

$481,452
Scott M Lippman · University Of Tx Md Anderson Can Ctr · P01 · FY2008 · CA

Nitric Oxide as a Modifier of Oxidative Stress

$481,426
David Wink · Division Of Clinical Sciences - Nci · ZIA · FY2016 · CA

Atlases to Report and Correlate Radiotherapy Dose Distributions with Outcomes

$481,389
Andrew Jackson · Sloan-Kettering Inst Can Research · R01 · FY2010 · CA

Olfactomedin 4 Suppresses Prostate Cancer Cell Growth and Metastasis via Negativ

$481,339
Griffin Rodgers · National Heart, Lung, And Blood Institute · ZIA · FY2018 · HL

Translation and Evaluation of a Multiparametric Prostate Cancer 3T Exam

$481,279
John Kurhanewicz · University Of California, San Francisco · R01 · FY2014 · CA

Development of SHP2 inhibitors for targeted anti-cancer therapy

$481,271
Zhong-Yin Zhang · Purdue University · R01 · FY2017 · CA

Bay Area Tumor Institute CCOP

$481,201
James Feusner · Bay Area Tumor Institute · U10 · FY2008 · CA

Cause and Effect Relationships Between Glycation and the Ancestry Specific Tumor Stroma

$481,094
David Paul Turner · Virginia Commonwealth University · R01 · FY2023 · CA

Resolving ensemble averaged conformations by multi-temperature x-ray crystallography

$481,088
James Solomon Fraser · University Of California, San Francisco · R01 · FY2018 · GM

INVESTIGATING ARHGEF2 IN PROMOTING NEURAL LINEAGE PLASTICITY AND TREATMENT RESISTANCE IN ADVANCED PROSTATE CANCER

$481,056
University Of California, Davis · · FY2025 · Defense Health Agency

Clinical Translation of a Large Oncosome-Based Prostate Cancer Blood Test

$480,986
Michael R Freeman · Cedars-Sinai Medical Center · R01 · FY2025 · CA

Greater Denver Latino Cancer Prevention/Control Network

$480,951
Estevan Tim Flores · University Of Colorado Denver · U01 · FY2006 · CA

A novel strategy to overcome drug resistance in cancer

$480,820
Aimee L Edinger · University Of California-Irvine · R01 · FY2023 · CA

INVESTIGATION OF THE UBIQUITIN LIGASE RNF31 AS A MEDIATOR OF IMMUNE EVASION IN ADVANCED PROSTATE CANCER

$480,640
Regents Of The University Of California, San Francisco, The · · FY2022 · Defense Health Agency

Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy

$480,634
James K Turkson · University Of Hawaii At Manoa · R01 · FY2016 · CA